Mutated or dysregulated transcription factors represent a unique class of drug targets that
mediate aberrant gene expression, including blockade of differentiation and cell death gene …

Structural analysis of modern pharmaceutical practices allows for the identification of two
rapidly growing trends: the introduction of tailor‐made amino acids and the exploitation of …

Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers.
Early identification of innate or acquired resistance mechanisms to these agents is essential …

Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
being wildly used as target therapy in non-small-cell lung cancer (NSCLC). However …

Background Intratumoral heterogeneity hampers the success of marker-based anticancer
treatment because the targeted therapy may eliminate a specific subpopulation of tumor …

Non‐small cell lung cancer (NSCLC) is one of the most deadly cancers worldwide, with poor
prognosis once the disease has progressed past the point at which surgery is a viable …

HER4 is a receptor tyrosine kinase that is required for the evolution of normal body systems
such as cardiovascular, nervous, and endocrine systems, especially the mammary glands. It …

Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The
discovery of several oncogenic driver mutations in patients with NSCLC has allowed the …

Additions of cysteine thiols to Michael acceptors underpin the mechanism of action of
several covalent drugs (eg, afatinib, osimertinib, ibrutinib, neratinib, and CC-292) …

Recent changes in lung cancer care, including new approvals in first line and the
introduction of high-throughput molecular technologies in routine testing led us to question …